# Envista Holdings Corporation (NVST) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $27.28, market value $4.4 billion.

## Valuation
- **P/E (trailing): 47.0×** (5-yr avg 41.9×, 3-yr avg 77.5×). Envista Holdings Corporation trades at 47.0× trailing earnings, close to its own five-year average of 41.9×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.16**. A PEG of 0.16 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.5×**. Each dollar of revenue is priced at 1.5×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.9×**. Enterprise value is 11.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.7%** (5-yr avg 5.3%). Free cash flow equals 5.7% of the market value, in line with its five-year average of 5.3%. Above 5% is generally attractive.
- **Earnings yield: 2.1%**. The inverse of the P/E: 2.1% of the price is earned each year.

## Profitability
- **Gross margin: 55.2%**. Envista Holdings Corporation keeps 55.2% of revenue after the direct cost of what it sells.
- **Operating margin: 9.6%**. 9.6% of revenue is left after running the business.
- **Net margin: 1.7%**. 1.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 1.5%**. 1.5% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 6.5%**. Return on all capital, debt included, is 6.5%.
- **Return on assets: 1.7%**. Each dollar of assets produces 1.7% of profit.

## Growth
- **Revenue growth (1 yr): 8.3%** (3-yr 1.9%/yr, 5-yr 7.1%/yr). Revenue grew 8.3% over the last year, against 7.1% a year compounded over five years.
- **EPS growth (1 yr): 104.3%** (3-yr -41.1%/yr, 5-yr 7.0%/yr). Earnings per share rose 104.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 29.1%/yr**. Free cash flow has compounded at 29.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.47**. Debt is 0.47 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Envista Holdings Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Envista Holdings Corporation; the consensus is buy, with an average price target of $30.79 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.3%** (YTD 25.7%, 3-mo 18.1%). The shares are up 31.3% over twelve months including dividends.
- **From 52-week high: -10.3%** (45.3% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.34** (volatility 37%). Beta of 1.34 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NVST · Page: https://foliofundamentals.com/stocks/nvst

Not investment advice.